beta cell pathophysiology

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Inzucchi, Silvio E; Bergenstal, Richard M; Buse, John B; Diamant, Michaela; Ferrannini, Ele; Nauck, Michael; Peters, Anne L; Tsapas, Apostolos; Wender, Richard; Matthews, David R
Diabetes care; 2012 Jun;35(6):1364-79. PMID: 22517736
Category: 
Guidelines
Tags: 
weight
thiazolidinediones (TZDs)
sulfonylureas (SUs)
prediabetes
metformin
lifestyle changes
insulin therapy
glycemic control
GLP-1 agonists
DPP-4 inhibitors
beta cell pathophysiology

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Nathan, David M; Buse, John B; Davidson, Mayer B; Heine, Robert J; Holman, Rury R; Sherwin, Robert; Zinman, Bernard
Diabetes care; 2006 Aug;29(8):1963-72. PMID: 16873813
Category: 
Guidelines
Tags: 
beta cell pathophysiology
DPP-4 inhibitors
GLP-1 agonists
glycemic control
insulin therapy
lifestyle changes
metformin
prediabetes
sulfonylureas (SUs)
thiazolidinediones (TZDs)
weight

The Good, The Bad, and the Ugly Part I: Why I’m not a Fan of the ADA/EASD’s 2012 Position Statement

Posted May 30, 2012 by John L. Leahy, MD
Tags: 
weight
thiazolidinediones (TZDs)
sulfonylureas (SUs)
prediabetes
metformin
lifestyle changes
insulin therapy
glycemic control
GLP-1 agonists
DPP-4 inhibitors
beta cell pathophysiology
The highly awaited ADA/EASD statement on management of type 2 diabetes was published online April 19th, 2012.1 I feel like a curmudgeon,but as a general statement, I’m not a fan. In fact, I’m worried that at best it will have little impact, and at worst could be harmful.

Beta Cell Failure: A Slippery Slope

Posted March 28, 2012 by John L. Leahy, MD
Tags: 
weight
thiazolidinediones (TZDs)
prediabetes
insulin therapy
GLP-1 agonists
DPP-4 inhibitors
beta cell pathophysiology

 In the past decade or so, our attempts to define the "earliest” events in Type 2 diabetes (T2DM) have moved increasingly earlier. We’re considering even the years before what we now consider to be the “pre-diabetes” stage—that is, years considerably before there are any clinical signs or symptoms of disease.

Cinnamon: A Therapeutic Alternative?

Posted February 22, 2012 by Doron Schneider, MD, FACP
Tags: 
prediabetes
insulin therapy
beta cell pathophysiology
Alternative medicine (also known as complementary medicine) has become a multibillion dollar industry. A subset of complementary medicine is dietary supplements–many of which may hold promise as adjuncts to more traditional therapies and treatments. The evidence basis for many of these ”therapies,” however, often remains immature and at best anecdotal in nature. 
 
At the same time interest amongst the public and traditional healthcare providers has increased in recent years, as have formal studies with increasing scientific rigor led by the NIH and other prominent aca

MODY: An Increasingly Important and Often Overlooked Form of Diabetes

Posted December 2, 2011 by Kevin A. Peterson, MD, MPH
Tags: 
glycemic control
beta cell pathophysiology
 Dr. Leahy and Dr. Hirsch provide a great introduction to the very latest info on MODY!  Dr. Leahy’s frank discussion of practical diagnostic considerations in patients with hyperglycemia who do not easily fit into the classification of type 1 or type 2 diabetes provides a refreshing look at how we practice today and a peek at how we may practice in the future. Dr.